Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
P/E ratio for Autolus Therapeutics plc (AUTL)
P/E ratio as of 2023: -5.38
According to Autolus Therapeutics plc's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.38. At the end of 2022 the company had a P/E ratio of -1.21.
P/E ratio history for Autolus Therapeutics plc from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.38 |
| 2022 | -1.21 |
| 2021 | -2.63 |
| 2020 | -3.24 |
| 2019 | -4.59 |
| 2018 | -31.08 |
| 2017 | -17.47 |
| 2016 | -27.46 |
| 2015 | -46.16 |